LAWRENCEVILLE, N.J.,
April 27, 2015 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN), an oncology drug
development company, today announced the appointment of
Harriet Shelare as Director,
Communications effective immediately. Ms. Shelare is an independent
counselor with more than 20 years' experience in healthcare public
relations, including media relations, issues management and public
education campaigns. She was formerly an Executive Vice President
for Ruder Finn Public Relations, where she headed US and Global
account teams for Novartis vaccines, and, earlier, as a Senior Vice
President for Femara, the Novartis aromatase inhibitor approved for
the treatment of early breast cancer. Previously, at MS&L
Public Relations, she headed the agency's support of Pfizer's
Celebrex in scientific data, regulatory activities, and medical
meeting presentations and data publications. As a Managing Director
for Hill & Knowlton's Healthcare Media Practice, she supported
numerous FDA approvals, product launches and public education
campaigns. She began in healthcare public relations as a media
relations manager for Memorial Sloan-Kettering Comprehensive Cancer
Center, after a career at CBS News and WCBS, where she was an
executive producer.
Ms. Shelare may be contacted at hshelare@celsion.com .
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer and
in Phase II development for the treatment of recurrent chest wall
breast cancer. The pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has three platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies, including TheraPlas™,
TheraSilence™ and RAST ™. For more information on Celsion,
visit our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking
statements in this release are made pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of
1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; the uncertainties of
and difficulties in analyzing interim clinical data, particularly
in small subgroups that are not statistically significant; FDA and
regulatory uncertainties and risks; the significant expense, time,
and risk of failure of conducting clinical trials; the need for
Celsion to evaluate its future development plans; possible
acquisitions or licenses of other technologies, assets or
businesses or the possible failure to make such acquisitions or
licenses; possible actions by customers, suppliers, competitors,
regulatory authorities; and other risks detailed from time to time
in the Celsion's periodic reports and prospectuses filed with the
Securities and Exchange Commission. Celsion assumes no
obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or
otherwise.
Celsion Investor Contact
Jeffrey W. Church
Senior Vice President and CFO
609-482-2455
jchurch@celsion.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/celsion-corporation-announces-appointment-of-harriet-shelare-to-director-communications-300071595.html
SOURCE Celsion Corporation